Invention Grant
- Patent Title: Methods and formulations for modulating Lyn kinase activity and treating related disorders
-
Application No.: US16286976Application Date: 2019-02-27
-
Publication No.: US11033548B2Publication Date: 2021-06-15
- Inventor: Andrew G. Reaume , Michael S. Saporito
- Applicant: Melior Pharmaceuticals I, Inc.
- Applicant Address: US PA Exton
- Assignee: Melior Pharmaceuticals I, Inc.
- Current Assignee: Melior Pharmaceuticals I, Inc.
- Current Assignee Address: US PA Exton
- Agency: Stradley Ronon Stevens & Young, LLP
- Main IPC: A61K31/513
- IPC: A61K31/513 ; A61K31/495 ; A61K45/00 ; A61K45/06 ; C07D239/52 ; A61K9/00 ; A61K31/505 ; A61K31/425 ; A61K31/498

Abstract:
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
Public/Granted literature
- US20190321362A1 Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders Public/Granted day:2019-10-24
Information query
IPC分类: